Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody - Associated small-vessel vasculitis: Comparison of two independent cohorts

Arthritis and Rheumatism

Volumn 58, Issue 9, 2008, Pages 2908-2918

  Pagnoux, Christian ^a   Hogan, Susan L ^b   Chin, Hyunsook ^b   Jennette, J Charles ^b   Falk, Ronald J ^b   Guillevin, Loïc ^a   Nachman, Patrick H ^b,c  

^a Université de Paris ^*  (France)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE;

ADD ON THERAPY; ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; FRANCE; GENDER; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RACE; RELAPSE; RESPIRATORY TRACT DISEASE; SMALL VESSEL VASCULITIS; UPPER RESPIRATORY TRACT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CYCLOPHOSPHAMIDE; FEMALE; FRANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGRESSION ANALYSIS; RISK FACTORS; SEX FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

EID: 51849091965     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23800     Document Type: Article

References (36)

1. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
2. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 1989;135:921-30.
3. Falk RJ, Hogan S, Carey TS, Jennette JC, for the Glomerular Disease Collaborative Network. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990;113:656-63.
4. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23-32.
5. De Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001;16:2018-27.
6. Briedigkeit L, Kettritz R, Gobel U, Natusch R. Prognostic factors in Wegener's granulomatosis. Postgrad Med J 1993;69:856-61.
7. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005;143:621-31.
8. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:33-9.
9. Haubitz M, Koch KM, Brunkhorst R. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 1998;13:2074-6.
10. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
11. Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985;56:467-83.
12. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, de Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002;47:326-32.
13. Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005;352:330-2.
14. Hagen EC, Ballieux BE, van Es LA, Daha MR, van der Woude FJ. Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences [review]. Blood 1993;81:1996-2002.
15. Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005;143:632-8.
16. Cohen P, Pagnoux C, Mahr A, Arene JP, Mouthon L, Le Guern V, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007;57:686-93.
17. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996;75:17-28.
18. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
19. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995;14:1707-23.
20. SAS/STAT software, release 8.2. Cary (NC): SAS Institute; 1989.
21. Guillevin L, Cohen P, Mahr A, Arene JP, Mouthon L, Puechal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003;49:93-100.
22. Mahr AD, Neogi T, Merkel PA. Epidemiology of Wegener's granulomatosis: lessons from descriptive studies and analyses of genetic and environmental risk determinants. Clin Exp Rheumatol 2006;24(2 Suppl 41):S82-91.
23. Watts RA, Scott DG. Epidemiology of the vasculitides. Semin Respir Crit Care Med 2004;25:455-64.
24. O'Donnell JL, Stevanovic VR, Frampton C, Stamp LK, Chapman PT. Wegener's granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. Intern Med J 2007;37:242-6.
25. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century: a disease of older patients. Rheumatology (Oxford) 2005;44:495-501.
26. Davis JW, Taira D, Chung RS. Health disparities in 30 indicators of recommended clinical care. J Healthc Qual 2006;28:32-41.
27. Daumit GL, Hermann JA, Powe NR. Relation of gender and health insurance to cardiovascular procedure use in persons with progression of chronic renal disease. Med Care 2000;38:354-65.
28. McMahon LF Jr, Wolfe RA, Huang S, Tedeschi P, Manning W Jr, Edlund MJ. Racial and gender variation in use of diagnostic colonic procedures in the Michigan Medicare population. Med Care 1999;37:712-7.
29. Chou AF, Scholle SH, Weisman CS, Bierman AS, Correa-de-Araujo R, Mosca L. Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues 2007;17:120-30.
30. Kyndt X, Reumaux D, Bridoux F, Tribout B, Bataille P, Hachulla E, et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999;106:527-33.
31. Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 2003;30:80-8.
32. Salama AD, Ryba M, Levy J, Pusey CD, Gaskin G. 30-year follow up of 400 patients with ANCA associated vasculitis: predictors of relapse and survival [abstract], J Am Soc Nephrol 2006;17:732A.
33. Popa ER, Stegeman CA, Abdulahad WH, van der MB, Arends J, Manson WM, et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007;46:1029-33.
34. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, De Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-17.
35. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis. Clin Exp Immunol 2003;132:496-504.
36. Bajema IM, Hagen EC, Hermans J, Noel LH, Waldherr R, Ferrario F, et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int 1999;56:1751-8.